Tolerrx

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.

Restorbio, located in Boston, is a pioneering company that encourages individuals to rethink aging through the lens of science. Their innovative pipeline includes massage guns and tools designed to enhance overall well-being and promote a healthier lifestyle. With a focus on cutting-edge technology and research, Restorbio is dedicated to providing solutions that empower individuals to take control of their aging process. By offering a range of products aimed at improving quality of life, Restorbio is at the forefront of the anti-aging industry. Generated from their website's infomation

Karyopharm Therapeutics is an innovation-driven pharmaceutical company based in Newton Center, MA. They are dedicated to the discovery, development, and commercialization of medicines aimed at improving the lives of patients with cancer and other major diseases. With a focus on oral Selective Inhibitor of Nuclear Export (SINE) technology, Karyopharm is a leader in addressing the fundamental mechanism of oncogenesis, the process through which healthy cells transform into cancer cells. They have a robust pipeline of four unique drug candidates in clinical development, targeting patients with cancer in both hematologic and solid tumors. At Karyopharm, patients are at the core of their mission. They are committed to developing important new medicines that can make a difference in patients' lives. With ongoing clinical trials for their lead drug candidate and next-generation programs, Karyopharm is actively exploring treatments in earlier lines of treatment, combination trials, and various tumor types across both hematologic and solid tumors. Their dedication to patients and innovative approach to drug development sets them apart in the pharmaceutical industry.Generated from the website